Resolution of the Council of Experts “Results of a multicenter, randomized, double-blind, placebo-controlled study of ARTNEO in patients with stage II–III primary knee osteoarthritis”
A. M. Lila,
L. I. Alekseeva,
I. B. Belyaeva,
I. B. Vinogradova,
N. A. Demidova,
O. V. Kalyuzhin,
I. I. Nesterovich,
V. N. Sorotskaya,
L. Yu. Shirokova,
S. P. Yakupova https://doi.org/10.14412/1996-7012-2023-6-136-142
Abstract
On August 31,2023 in V.A. Nasonova Research Institute of Rheumatology a meeting of the Expert Council was held at which the principal investigators and co-investigators of the ARTNEO-2021 protocol "Multicenter randomized double-blind, placebo-controlled study of ARTNEO in patients with stage II-III primary knee osteoarthritis" was held. A consensus position was developed on the possibility and feasibility of using a combination of undenatured (native) type II collagen, methylsulfonylmethane, boswellic acids, vitamins C and D (ARTNEO complex) in clinical practice. Based on the results of the study, the use of the ARTNEO complex can be recommended as part of a complex therapy for patients with osteoarthritis as a course treatment with total duration up to 6 months. The results of the study can only be interpreted in relation to ARTNEO and cannot be transferred to preparations with a different composition.
About the Authors
A. M. Lila
V.A. Nasonova Research Institute of Rheumatology;
Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522;
Department of Rheumatology, 2/1, Barrikadnaya Street, Build. 1, Moscow 125993
L. I. Alekseeva
V.A. Nasonova Research Institute of Rheumatology;
Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522;
Department of Rheumatology, 2/1, Barrikadnaya Street, Build. 1, Moscow 125993
I. B. Belyaeva
North-Western State Medical University named after I.I. Mechnikov, Ministry of Health of Russia
Russian Federation
Russian Federation
41, Kirochnaya Street, St. Petersburg 191015
I. B. Vinogradova
Ulyanovsk Regional Clinical Hospital
Russian Federation
Russian Federation
7, III Internatzional Street, Ulyanovsk 432063
N. A. Demidova
Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
1, Ostrovitianov Street, Moscow 117997
O. V. Kalyuzhin
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
8, Trubetskaya Street, Build. 2, Moscow 119991
I. I. Nesterovich
Pavlov First Saint-Petersburg State Medical University (Pavlov University), Ministry
of Health of Russia
Russian Federation
Russian Federation
6–8, Lva Tolstogo Street, Saint-Petersburg 197022
V. N. Sorotskaya
Tula State University, Medical Institute
Russian Federation
Russian Federation
128, Boldin Street, Tula 300028
L. Yu. Shirokova
Yaroslavl State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
5, Revolutzionnaya Street, Yaroslavl 150000
S. P. Yakupova
Kazan State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
49, Butlerov Street, Kazan 420012
References
1. Yao Q, Wu X, Tao C, et al. Osteoarthritis: pathogenic signaling pathways and therapeutic targets. Signal Transduct Target Ther. 2023 Feb 3;8(1):56. doi: 10.1038/s41392-023-01330-w.
2. Hawker GA, King LK. The Burden of Osteoarthritis in Older Adults. Clin Geriatr Med. 2022 May;38(2):181-192. doi: 10.1016/j.cger.2021.11.005.
3. Favero M, Belluzzi E, Ortolan A, et al. Erosive hand osteoarthritis: latest findings and outlook. Nat Rev Rheumatol. 2022 Mar;18(3): 171-183. doi: 10.1038/s41584-021-00747-3. Epub 2022 Feb 1.
4. Conaghan PG, Abraham L, Graham-Clarke P, et al. OP0190 Understanding current prescription drug treatment paradigms for patients with osteoarthritis in Europe. Ann Rheum Dis. 2020;79:118.
5. Namba RS, Inacio MC, Pratt NL, et al. Postoperative opioid use as an early indication of total hip arthroplasty failure. Acta Orthop. 2016 Jul;87 Suppl 1(Suppl 1):37-43. doi: 10.1080/17453674.2016.1181820. Epub 2016 May 11.
6. Conley B, Bunzli S, Bullen J, et al. Core Recommendations for Osteoarthritis Care: A Systematic Review of Clinical Practice Guidelines. Arthritis Care Res (Hoboken). 2023 Sep;75(9):1897-1907. doi: 10.1002/acr.25101. Epub 2023 Mar 17.
7. Resolution of the consensus of experts of the Russian Federation on the diagnosis and treatment of osteoarthritis for primary care physicians. Terapiya. 2022;8(5):119-128. (In Russ.).
8. Honvo G, Lengele L, Charles A, et al. Role of Collagen Derivatives in Osteoarthritis and Cartilage Repair: A Systematic Scoping Review With Evidence Mapping. Rheumatol Ther. 2020 Dec;7(4):703-740. doi: 10.1007/s40744-020-00240-5. Epub 2020 Oct 17.
9. Lugo JP, Saiyed ZM, Lane NE. Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study. Nutr J. 2016 Jan 29;15:14. doi: 10.1186/s12937-016-0130-8.
10. Crowley DC, Lau FC, Sharma P, et al. Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial. Int J Med Sci. 2009 Oct 9;6(6):312-21. doi: 10.7150/ijms.6.312.
11. Liu X, Machado GC, Eyles JP, et al. Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis. Br J Sports Med. 2018 Feb;52(3):167-175. doi: 10.1136/bjsports-2016-097333. Epub 2017 Oct 10.
12. Nagler-Anderson C, Bober LA, Robinson ME, et al. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci U S A. 1986 Oct;83(19):7443-6. doi: 10.1073/pnas.83.19.7443.
13. Milojevic D, Nguyen KD, Wara D, Mellins ED. Regulatory T cells and their role in rheumatic diseases: a potential target for novel therapeutic development. Pediatr Rheumatol Online J. 2008 Dec 1:6:20. doi: 10.1186/1546-0096-6-20.
14. Tordesillas L, Berin MC. Mechanisms of Oral Tolerance. Clin Rev Allergy Immunol. 2018 Oct;55(2):107-117. doi: 10.1007/s12016-018-8680-5.
15. Faria AM, Weiner HL. Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol. 2006 Jun-Dec; 13(2-4):143-57. doi: 10.1080/17402520600876804.
16. Bagchi D, Misner B, Bagchi M, et al. Effects of orally administered undenatured type II collagen against arthritic inflammatory diseases: a mechanistic exploration. Int J Clin Pharmacol Res. 2002;22(3-4):101-10.
17. Collagenase and rheumatoid arthritis. N Engl J Med. 1968 Oct 24;279(17):942-3. doi: 10.1056/NEJM196810242791710.
18. Mabbott NA, Donaldson DS, Ohno H, et al. Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium. Mucosal Immunol. 2013 Jul;6(4):666-77. doi: 10.1038/mi.2013.30. Epub 2013 May 22.
19. Pabst O, Mowat AM. Oral tolerance to food protein. Mucosal Immunol. 2012 May; 5(3):232-9. doi: 10.1038/mi.2012.4. Epub 2012 Feb 8.
20. Wambre E, Jeong D. Oral Tolerance Development and Maintenance. Immunol Allergy Clin North Am. 2018 Feb;38(1):27-37. doi: 10.1016/j.iac.2017.09.003. Epub 2017 Oct 26.
21. Lv Z, Yang YX, Li J, et al. Molecular Classification of Knee Osteoarthritis. Front Cell Dev Biol. 2021 Aug 27;9:725568. doi: 10.3389/fcell.2021.725568.
22. National Academies of Sciences, Engineering, and Medicine. Developing Multimodal Therapies for Brain Disorders: Proceedings of a Workshop. Washington: The National Academies Press; 2017.
23. Mahajan R, Rathod NR, Narayanan V. (2019). Multimodal Anti-Inflammatory Approach to Osteoarthritis Management – Review of T Cell Immunomodulation with Undenatured (Native) Collagen Type II, and LOX Inhibition with Boswellia. Nov Tech Arthritis Bone Res. 2019;3(4):555618. doi: 10.19080/NTAB.2019.03.555618.
24. Zapata A, Fernandez-Parra R. Management of Osteoarthritis and Joint Support Using Feed Supplements: A Scoping Review of Undenatured Type II Collagen and Boswellia serrata. Animals (Basel). 2023 Feb 27;13(5): 870. doi: 10.3390/ani13050870.
25. Jain AV, Jain KA, Vijayaraghavan N. AflaB2® and Osteoarthritis: A Multicentric, Observational, Post-Marketing Surveillance Study in Indian Patients Suffering from Knee Osteoarthritis. Int J Res Orthop. 2021 Jan;7(1): 110-115. doi: 10.18203/issn.2455-4510. IntJResOrthop20205570.
26. Sadigursky D, Sanches M, Garcia N, et al. Effectiveness of the use of non-hydrolysed type II collagen in the treatment of osteoarthritis: a systematic review and meta-analysis. Brazilian Journal of Health Review. 2023; 6(1):1649-1660. doi:10.34119/bjhrv6n1-131.
27. Yu G, Xiang W, Zhang T, et al. Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis. BMC Complement Med Ther. 2020 Jul 17;20(1):225. doi: 10.1186/s12906-020-02985-6.
28. Cameron M, Chrubasik S. Oral herbal therapies for treating osteoarthritis. Cochrane Database Syst Rev. 2014 May 22;2014(5): CD002947. doi: 10.1002/14651858. CD002947.pub2.
29. Gwinnutt JM, Wieczorek M, Rodriguez-Carrio J, et al. Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. RMD Open. 2022 Jun; 8(2):e002167. doi: 10.1136/rmdopen-2021-002167.
30. Neogi T, Colloca L. Placebo effects in osteoarthritis: implications for treatment and drug development. Nat Rev Rheumatol. 2023 Oct;19(10):613-626. doi: 10.1038/s41584- 023-01021-4. Epub 2023 Sep 11.
Review
For citations:
Lila AM, Alekseeva LI, Belyaeva IB, Vinogradova IB, Demidova NA, Kalyuzhin OV, Nesterovich II, Sorotskaya VN, Shirokova LY, Yakupova SP. Resolution of the Council of Experts “Results of a multicenter, randomized, double-blind, placebo-controlled study of ARTNEO in patients with stage II–III primary knee osteoarthritis”. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2023;17(6):136-142. (In Russ.) https://doi.org/10.14412/1996-7012-2023-6-136-142
Views:
2105
Email this article 